*ST吉药
(300108)
| 流通市值：1.37亿 | | | 总市值：1.40亿 |
| 流通股本：6.53亿 | | | 总股本：6.66亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 156,272,854.3 | 63,743,551.35 | 333,330,280.33 | 254,832,693.5 |
| 营业收入 | 156,272,854.3 | 63,743,551.35 | 333,330,280.33 | 254,832,693.5 |
| 二、营业总成本 | 250,880,121.68 | 117,464,571.89 | 597,999,649.94 | 448,087,921.36 |
| 营业成本 | 98,254,185.82 | 37,880,319.69 | 222,590,912.13 | 160,410,129.72 |
| 税金及附加 | 5,700,985.26 | 2,691,366.76 | 12,686,829.7 | 10,235,725.9 |
| 销售费用 | 22,128,391.44 | 10,976,344.75 | 76,065,472.66 | 62,324,597.87 |
| 管理费用 | 41,415,188.73 | 22,482,399.31 | 103,025,833 | 79,659,680.68 |
| 研发费用 | 1,804,693.71 | 1,541,058.75 | 9,864,245.01 | 5,307,154.95 |
| 财务费用 | 81,576,676.72 | 41,893,082.63 | 173,766,357.44 | 130,150,632.24 |
| 其中:利息费用 | 81,555,775.74 | 40,150,960.65 | 173,715,476.75 | 122,790,746.96 |
| 其中:利息收入 | 14,702.59 | 9,474.45 | 95,364.88 | 81,915.36 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -4,015,483 | 27,125 | 31,227,551.62 | 467,149.89 |
| 资产处置收益 | -23,593.71 | -23,593.71 | 487,764.55 | 587,478.32 |
| 资产减值损失(新) | -1,876,115.13 | 433,980.81 | -285,824,270.21 | -43,913,014.14 |
| 信用减值损失(新) | 107,235.14 | 459,421.41 | -10,517,683.72 | -21,063,490.82 |
| 其他收益 | 228,081.32 | 128,842.82 | 1,335,872.48 | 956,135.24 |
| 四、营业利润 | -100,187,142.76 | -52,695,244.21 | -527,960,134.89 | -256,220,969.37 |
| 加:营业外收入 | 26,705.45 | 880.45 | 231,459.82 | 148,741.57 |
| 减:营业外支出 | 7,664,115.24 | 8,459,368.05 | 97,338,940.8 | 31,005,098.46 |
| 五、利润总额 | -107,824,552.55 | -61,153,731.81 | -625,067,615.87 | -287,077,326.26 |
| 减:所得税费用 | 3,056,325.68 | 1,615,723.98 | 4,414,370.44 | 6,882,381.73 |
| 六、净利润 | -110,880,878.23 | -62,769,455.79 | -629,481,986.31 | -293,959,707.99 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -110,880,878.23 | -62,769,455.79 | -629,481,986.31 | -293,959,707.99 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -81,717,110.65 | -45,174,602.67 | -439,433,948.13 | -231,236,923.98 |
| 少数股东损益 | -29,163,767.58 | -17,594,853.12 | -190,048,038.18 | -62,722,784.01 |
| 扣除非经常损益后的净利润 | -78,836,930.18 | -39,314,178.56 | -410,060,141 | -210,054,912.34 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.12 | -0.07 | -0.66 | -0.35 |
| (二)稀释每股收益 | -0.12 | -0.07 | -0.66 | -0.35 |
| 八、其他综合收益 | - | - | -66,762,411.96 | - |
| 归属于母公司股东的其他综合收益 | - | - | -56,413,611.96 | - |
| 九、综合收益总额 | -110,880,878.23 | -62,769,455.79 | -696,244,398.27 | -293,959,707.99 |
| 归属于母公司股东的综合收益总额 | -81,717,110.65 | -45,174,602.67 | -495,847,560.09 | -231,236,923.98 |
| 归属于少数股东的综合收益总额 | -29,163,767.58 | -17,594,853.12 | -200,396,838.18 | -62,722,784.01 |
| 公告日期 | 2025-08-29 | 2025-04-29 | 2025-04-29 | 2024-10-30 |
| 审计意见(境内) | | | 无法表示意见 | |